David Hoang
Stock Analyst at Deutsche Bank
(4.67)
# 917
Out of 5,090 analysts
127
Total ratings
53.9%
Success rate
25.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Hoang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CLYM Climb Bio | Initiated Coverage: Buy | $28 | $10.25 | +173.17% | 1 | Oct 20, 2026 | |
| HRMY Harmony Biosciences Holdings | Reiterated: Hold | $39 → $42 | $38.76 | +8.36% | 9 | Oct 1, 2026 | |
| AXSM Axsome Therapeutics | Reiterated: Buy | $280 → $267 | $144.43 | +84.86% | 10 | Sep 29, 2026 | |
| ACAD Acadia Pharmaceuticals | Reiterated: Buy | $38 → $31 | $20.59 | +50.56% | 12 | Sep 25, 2026 | |
| XENE Xenon Pharmaceuticals | Downgraded: Hold | $90 → $46 | $37.41 | +22.96% | 10 | Sep 18, 2026 | |
| RYTM Rhythm Pharmaceuticals | Initiated Coverage: Hold | $120 | $92.57 | +29.63% | 1 | Aug 27, 2026 | |
| JAZZ Jazz Pharmaceuticals | Reiterated: Buy | $287 → $300 | $215.98 | +38.90% | 8 | Aug 26, 2026 | |
| SYRE Spyre Therapeutics | Reiterated: Buy | $135 → $127 | $96.56 | +31.52% | 5 | Aug 26, 2026 | |
| NBIX Neurocrine Biosciences | Rated: Hold | $190 → $165 | $146.10 | +12.94% | 12 | Aug 13, 2026 | |
| KYMR Kymera Therapeutics | Initiated Coverage: Hold | $120 | $126.63 | -5.24% | 1 | Jul 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $31 → $35 | $18.94 | +84.79% | 10 | Jul 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $65 → $20 | $15.42 | +29.70% | 2 | Jun 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $420 → $374 | $285.93 | +30.80% | 9 | Jun 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $12 → $14 | $18.62 | -24.81% | 23 | Mar 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $52 → $45 | $45.34 | -0.75% | 3 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $7 | $0.2101 | n/a | 1 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $16 | $6.20 | n/a | 3 | Jul 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $16 | $1.72 | n/a | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $220 | $165.00 | n/a | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $80 | $59.90 | n/a | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $24 → $3 | $10.38 | n/a | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19 | $0.3878 | n/a | 1 | Sep 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $73 | $332.29 | n/a | 1 | Mar 12, 2020 |
Climb Bio
Oct 20, 2026
Initiated Coverage: Buy
Price Target: $28
Current: $10.25
Upside: +173.17%
Harmony Biosciences Holdings
Oct 1, 2026
Reiterated: Hold
Price Target: $39 → $42
Current: $38.76
Upside: +8.36%
Axsome Therapeutics
Sep 29, 2026
Reiterated: Buy
Price Target: $280 → $267
Current: $144.43
Upside: +84.86%
Acadia Pharmaceuticals
Sep 25, 2026
Reiterated: Buy
Price Target: $38 → $31
Current: $20.59
Upside: +50.56%
Xenon Pharmaceuticals
Sep 18, 2026
Downgraded: Hold
Price Target: $90 → $46
Current: $37.41
Upside: +22.96%
Rhythm Pharmaceuticals
Aug 27, 2026
Initiated Coverage: Hold
Price Target: $120
Current: $92.57
Upside: +29.63%
Jazz Pharmaceuticals
Aug 26, 2026
Reiterated: Buy
Price Target: $287 → $300
Current: $215.98
Upside: +38.90%
Spyre Therapeutics
Aug 26, 2026
Reiterated: Buy
Price Target: $135 → $127
Current: $96.56
Upside: +31.52%
Neurocrine Biosciences
Aug 13, 2026
Rated: Hold
Price Target: $190 → $165
Current: $146.10
Upside: +12.94%
Kymera Therapeutics
Jul 29, 2026
Initiated Coverage: Hold
Price Target: $120
Current: $126.63
Upside: -5.24%
Jul 16, 2026
Rated: Buy
Price Target: $31 → $35
Current: $18.94
Upside: +84.79%
Jun 26, 2026
Rated: Buy
Price Target: $65 → $20
Current: $15.42
Upside: +29.70%
Jun 2, 2026
Reiterated: Buy
Price Target: $420 → $374
Current: $285.93
Upside: +30.80%
Mar 26, 2026
Reiterated: Sell
Price Target: $12 → $14
Current: $18.62
Upside: -24.81%
Nov 13, 2025
Reiterated: Buy
Price Target: $52 → $45
Current: $45.34
Upside: -0.75%
Jul 25, 2024
Initiated Coverage: Buy
Price Target: $7
Current: $0.2101
Upside: n/a
Jul 17, 2024
Reiterated: Buy
Price Target: $16
Current: $6.20
Upside: n/a
Mar 6, 2024
Reiterated: Buy
Price Target: $16
Current: $1.72
Upside: n/a
Apr 26, 2023
Initiated Coverage: Hold
Price Target: $220
Current: $165.00
Upside: n/a
Apr 26, 2023
Initiated Coverage: Buy
Price Target: $80
Current: $59.90
Upside: n/a
Dec 7, 2022
Downgraded: Hold
Price Target: $24 → $3
Current: $10.38
Upside: n/a
Sep 30, 2020
Reiterated: Buy
Price Target: $19
Current: $0.3878
Upside: n/a
Mar 12, 2020
Initiated Coverage: Buy
Price Target: $73
Current: $332.29
Upside: n/a